Charles Schwab’s Spyre Therapeutics SYRE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.26M | Buy |
418,503
+35,867
| +9% | +$537K | ﹤0.01% | 2235 |
|
|
2025
Q1 | $6.17M | Buy |
382,636
+2,986
| +0.8% | +$48.2K | ﹤0.01% | 2182 |
|
|
2024
Q4 | $8.84M | Buy |
379,650
+46,375
| +14% | +$1.08M | ﹤0.01% | 2072 |
|
|
2024
Q3 | $9.8M | Buy |
333,275
+235,094
| +239% | +$6.91M | ﹤0.01% | 2032 |
|
|
2024
Q2 | $2.31M | Buy |
98,181
+83,181
| +555% | +$1.96M | ﹤0.01% | 2662 |
|
|
2024
Q1 | $569K | Buy |
+15,000
| New | +$569K | ﹤0.01% | 2972 |
|
|
2022
Q2 | – | Sell |
-106,810
| Closed | -$246K | – | 3636 |
|
|
2022
Q1 | $246K | Buy |
106,810
+7,333
| +7% | +$16.9K | ﹤0.01% | 3270 |
|
|
2021
Q4 | $473K | Hold |
99,477
| – | – | ﹤0.01% | 3163 |
|
|
2021
Q3 | $791K | Sell |
99,477
-6,302
| -6% | -$50.1K | ﹤0.01% | 2966 |
|
|
2021
Q2 | $737K | Sell |
105,779
-5,004
| -5% | -$34.9K | ﹤0.01% | 3035 |
|
|
2021
Q1 | $878K | Sell |
110,783
-1,641
| -1% | -$13K | ﹤0.01% | 2899 |
|
|
2020
Q4 | $885K | Buy |
112,424
+6,771
| +6% | +$53.3K | ﹤0.01% | 2811 |
|
|
2020
Q3 | $750K | Sell |
105,653
-3,193
| -3% | -$22.7K | ﹤0.01% | 2753 |
|
|
2020
Q2 | $1.01M | Buy |
108,846
+48,286
| +80% | +$447K | ﹤0.01% | 2625 |
|
|
2020
Q1 | $283K | Buy |
60,560
+939
| +2% | +$4.39K | ﹤0.01% | 2913 |
|
|
2019
Q4 | $456K | Hold |
59,621
| – | – | ﹤0.01% | 2853 |
|
|
2019
Q3 | $459K | Hold |
59,621
| – | – | ﹤0.01% | 2832 |
|
|
2019
Q2 | $409K | Buy |
59,621
+15,110
| +34% | +$104K | ﹤0.01% | 2903 |
|
|
2019
Q1 | $359K | Buy |
44,511
+3,351
| +8% | +$27K | ﹤0.01% | 2886 |
|
|
2018
Q4 | $309K | Buy |
41,160
+10,860
| +36% | +$81.5K | ﹤0.01% | 2925 |
|
|
2018
Q3 | $290K | Hold |
30,300
| – | – | ﹤0.01% | 3011 |
|
|
2018
Q2 | $321K | Buy |
+30,300
| New | +$321K | ﹤0.01% | 2934 |
|